<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18143" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Barrett Esophagus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khieu</surname>
            <given-names>Michelle</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukherjee</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Creighton University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michelle Khieu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Mukherjee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18143.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Barrett esophagus is a premalignant condition partly related to esophageal reflux, characterized by gastric and, more importantly, intestinal columnar metaplasia of the normally squamous mucosa of the distal esophagus. The&#x000a0;columnar epithelium in the affected portion of the esophagus may become dysplastic and subsequently progress to esophageal adenocarcinoma or adenocarcinoma of the esophagogastric junction. This&#x000a0;progression occurs&#x000a0;in steps, therefore, mucosal biopsies of the esophagus may not show dysplasia, or show indefinite, low- or high-grade dysplasia, or cancer. Because this progression occurs over many years, there are opportunities to screen for&#x000a0;Barrett mucosa&#x000a0;in high-risk individuals, to monitor the condition periodically over several years after Barrett mucosa is identified, and to treat the pathology in various ways at each step of the progression. Intensified medical therapy to reduce acid reflux is the first step in managing Barrett esophagus, whether or not symptomatic reflux is being treated adequately. While esophagectomy was the only treatment option for high-grade dysplasia and cancer in past years, there are now various endoscopic options for resection or destruction of the affected tissue.</p>
        <p>This activity illustrates the pathophysiology, risk factors, diagnostic criteria,&#x000a0;treatment, and complications&#x000a0;of Barrett esophagus&#x02014;including the importance of histological assessment, the role of endoscopic surveillance, and the integration of novel therapies into clinical practice. The activity also highlights the role of an interprofessional healthcare team in optimizing treatment strategies and enhancing patient outcomes in clinical practice.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen high-risk patients for Barrett esophagus using the latest evidence-based guidelines.</p></list-item><list-item><p>Implement a&#x000a0;surveillance plan for patients diagnosed with Barrett esophagus, irrespective of the presence of dysplasia or early malignancy.</p></list-item><list-item><p>Identify&#x000a0;current treatment options for patients with Barrett esophagus, including medication, endoscopic eradication therapy, and surgery.</p></list-item><list-item><p>Collaborate with an interprofessional team to optimize clinical care and outcomes&#x000a0;for patients with Barrett esophagus.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18143&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18143">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18143.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Barrett esophagus is a premalignant condition characterized by salmon-colored mucosa extending at least 1 cm proximal to the gastroesophageal junction, with biopsies showing columnar epithelium and goblet cells indicative of intestinal metaplasia.<xref ref-type="bibr" rid="article-18143.r1">[1]</xref> Most cases are acquired, with the precipitant usually being long-standing gastroesophageal reflux (GERD). Barrett esophagus can be found in 5% to 12% of patients with chronic symptoms of GERD.<xref ref-type="bibr" rid="article-18143.r2">[2]</xref>&#x000a0;Some&#x000a0;families have a rare but increased incidence of developing&#x000a0;Barrett esophagus through autosomal dominant inheritance of certain susceptibility alleles, known as the familial Barrett esophagus phenotype.&#x000a0;</p>
        <p>The condition predisposes patients to developing dysplasia and esophageal adenocarcinoma, a cancer with high morbidity and mortality that has been increasing in incidence over the past 50 years.<xref ref-type="bibr" rid="article-18143.r2">[2]</xref> Surveillance programs have been developed to aid management decisions based on the presence of nondysplastic Barrett esophagus; indeterminate, low- and high-grade dysplasia; or invasive adenocarcinoma. These protocols continue to change as new studies and data are evaluated and included in newer guidelines.&#x000a0;Specific indications for various endoscopic and surgical therapies have recently changed. Advances in endoscopic eradication technology and further studies for patient risk stratification are research areas of interest with the potential to affect future guidelines for diagnosing and managing Barrett esophagus cases.<xref ref-type="bibr" rid="article-18143.r3">[3]</xref><xref ref-type="bibr" rid="article-18143.r4">[4]</xref><xref ref-type="bibr" rid="article-18143.r5">[5]</xref></p>
      </sec>
      <sec id="article-18143.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Most patients with Barrett esophagus have a known history of chronic GERD, the reflux of&#x000a0;gastric acid&#x000a0;and bile through the lower esophageal sphincter and into the distal esophagus. The stomach lining is a mucinous columnar epithelium that can&#x000a0;withstand the acidic environment required for digestion, and the esophagus&#x000a0;is lined&#x000a0;by a squamous epithelium; as a response to the acidic irritant, the squamous epithelium becomes inflamed. Continued exposure to acids leads to persistent inflammation and a columnar metaplastic reaction with the eventual development of an intestinal-type phenotype characterized by goblet cells.<xref ref-type="bibr" rid="article-18143.r6">[6]</xref></p>
        <p>Why Barrett esophagus develops in some patients with GERD and not in others remains unclear. However, additional risk factors for developing Barrett esophagus include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Male genotype</p>
          </list-item>
          <list-item>
            <p>Non-Hispanic White&#x000a0;race</p>
          </list-item>
          <list-item>
            <p>Age&#x000a0;older than 50 years</p>
          </list-item>
          <list-item>
            <p>Central obesity</p>
          </list-item>
          <list-item>
            <p>Past or present smoking history</p>
          </list-item>
          <list-item>
            <p>Family history of either Barrett esophagus or esophageal adenocarcinoma in a first-degree relative</p>
          </list-item>
          <list-item>
            <p>Genetics: inconclusive evidence&#x000a0;that specific genetic mutations may increase the risk of Barrett esophagus</p>
          </list-item>
        </list>
        <p>Patients with chronic reflux and at least&#x000a0;3 of these other risk factors are considered to be at high risk and should undergo screening endoscopy.<xref ref-type="bibr" rid="article-18143.r2">[2]</xref></p>
      </sec>
      <sec id="article-18143.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Barrett esophagus is&#x000a0;usually but not always found in patients with GERD. The prevalence is 0.8% in the&#x000a0;general population,&#x000a0;3% in patients with GERD,&#x000a0;12.2% with GERD plus any other risk factor, 23.4% with a family history of Barrett esophagus or esophageal adenocarcinoma,&#x000a0;6.1% in individuals older than 50,&#x000a0;1.9% in people with obesity, and 6.8% in men. The prevalence of Barrett esophagus&#x000a0;increases linearly with more risk factors, with each additional risk factor adding 1.2%.<xref ref-type="bibr" rid="article-18143.r7">[7]</xref>&#x000a0;The condition is the only known&#x000a0;endoscopically identifiable precursor lesion for esophageal adenocarcinoma. Both Barrett esophagus and adenocarcinoma are much more common in men than in women, by ratios of 2:1 and 9:1, respectively.</p>
        <p>The overall incidence of GERD, Barrett esophagus, and esophageal adenocarcinoma has been increasing significantly over the last 3 to 5 decades, partially attributable to increased numbers of endoscopies. However, fewer than 5% of patients with Barrett esophagus will develop esophageal adenocarcinoma. Study results indicate the absolute annual risk of adenocarcinoma in nondysplastic Barrett esophagus is 0.1% to 0.5% per year, a highly variable 1% to 43% per year for low-grade dysplasia, and 23% to 60% per year for high-grade dysplasia. A greater extent of dysplasia has a significantly higher risk of cancer, as well as the presence of&#x000a0;an endoscopic abnormality, such as a nodule or mass.<xref ref-type="bibr" rid="article-18143.r8">[8]</xref><xref ref-type="bibr" rid="article-18143.r9">[9]</xref></p>
      </sec>
      <sec id="article-18143.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathogenesis of Barrett esophagus remains to be elucidated; however, it is believed to be a response to long-standing GERD. Some progress has been made in determining the molecular alterations and primary cell types involved. Study results have indicated that exposure to acid induces the squamous epithelial cells to secrete inflammatory cytokines such as interleukin 8 and interleukin 1b, which act to mediate the inflammatory response and signal T lymphocytes and neutrophils to migrate into the epithelium. Bile acids, specifically, have been shown to upregulate <italic toggle="yes">CDX2</italic>, the intestinal differentiation factor, and <italic toggle="yes">MUC2</italic>, the goblet cell-specific gene, within normal columnar and esophageal cancer cell lines.</p>
        <p>Up to 90% of&#x000a0;affected patients have a detectable clonal aberration of the p16 tumor suppressor gene. <italic toggle="yes">CDX2</italic> and <italic toggle="yes">TP53</italic> mutations are early molecular alterations found in metaplastic columnar epithelium even before morphologic dysplasia is recognized. However, immunohistochemical staining to evaluate these markers is not currently recommended in routine diagnostic cases of Barrett esophagus.</p>
        <p>Results from a recent study described a population of possible embryonic stem cells at the squamocolumnar junction. In contrast, other studies suggest that stem cells derived from undifferentiated mesenchymal cells in the lamina propria of the esophagus or the bone marrow may be the cell of origin for Barrett esophagus.&#x000a0;Columnar epithelium develops first in the esophagus, possibly beginning as gastric-type mucinous epithelium, reprogramming to intestinal differentiation and, ultimately, goblet cells.<xref ref-type="bibr" rid="article-18143.r10">[10]</xref>&#x000a0;There is evidence of a type of epithelium known as multilayered epithelium, which shows combined squamous and columnar features, likely representing an intermediate phase within the metaplastic reaction. The multilayered epithelium is strongly associated with&#x000a0;reflux esophagitis and expresses a mucin and cytokeratin profile similar to&#x000a0;Barrett esophagus columnar epithelium and intestinal transcription factors. Further studies are needed to understand the complete mechanism of pathogenesis.<xref ref-type="bibr" rid="article-18143.r6">[6]</xref><xref ref-type="bibr" rid="article-18143.r5">[5]</xref></p>
      </sec>
      <sec id="article-18143.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In Barrett esophagus, the normal esophageal squamous epithelium is replaced by intestinal-type mucosa characterized by columnar epithelium and&#x000a0;usually with goblet cells (see <bold>Image.</bold> Barrett Esophagus). Nondysplastic Barrett epithelium may demonstrate nuclear enlargement and stratification in the basal glands, but the surface is mature. Dysplasia is identified by neoplasia limited to the basement membrane. Characteristic pathologic features include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Indefinite dysplasia: This type of neoplasia cannot be described as gastric, intestinal,&#x000a0;or&#x000a0;serrated differentiation.&#x000a0;This terminology may be chosen if there is extensive regenerative change so much that the atypia present slightly overlaps with low-grade dysplasia. Still, unequivocal pathologic evidence of dysplasia is not found.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Low-grade intestinal dysplasia: Goblet cells with enlargement and elongation of nuclei, increased numbers of lymphocytes, an increased nuclear-to-cytoplasmic ratio, and nuclear stratification involving the basal half of cellular cytoplasm characterize this type of dysplasia. Increased mitoses are mostly limited to the crypts, with few, if any, atypical mitoses.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>High-grade intestinal dysplasia: This type of dysplasia includes a greater degree of nuclear enlargement and number of lymphocytes; nuclear stratification of the full thickness of the mucosa with nuclear pleomorphism, irregular nuclear shapes, and significant loss of nuclear polarity; mitoses are seen on the surface with atypical mitoses.<xref ref-type="bibr" rid="article-18143.r10">[10]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Intramucosal carcinoma: In this carcinoma, lamina propria&#x000a0;is invaded by individual neoplastic cells with no connection to the crypts, sheeting out of malignant cells, irregular and angulated glands located&#x000a0;in the lamina propria or muscularis mucosae&#x02014;a complex anastomosing pattern of glands within the lamina propria, and/or back-to-back glands or cells in an irregular architectural pattern.<xref ref-type="bibr" rid="article-18143.r11">[11]</xref><xref ref-type="bibr" rid="article-18143.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>Gastric metaplasia of the distal esophagus is distinguished from intestinal metaplasia, and the risk of esophageal adenocarcinoma is much lower with gastric metaplasia than with intestinal metaplasia. There is uncertainty about whether&#x000a0;gastric metaplasia increases the risk of esophageal adenocarcinoma significantly or not. This concept is supported by the evidence that&#x000a0;intestinal metaplasia demonstrates certain genomic hallmarks of esophageal adenocarcinoma, which is much less significant than&#x000a0;gastric metaplasia in the absence of intestinal metaplasia.<xref ref-type="bibr" rid="article-18143.r13">[13]</xref></p>
      </sec>
      <sec id="article-18143.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients with Barrett esophagus will exhibit symptoms of GERD, such as heartburn (retrosternal burning), especially after eating. Acid regurgitation is another likely symptom. Other possible&#x000a0;symptoms, though less common, include dysphagia, a sore throat, hoarseness, chest pain, chronic cough, melena, or weight loss.&#x000a0;Some patients&#x000a0;are asymptomatic. Typically, patients will have a chronic history of GERD symptoms with no specific physical examination findings.</p>
      </sec>
      <sec id="article-18143.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In 2022, the American College of Gastroenterology (ACG) published new clinical guidelines for diagnosing and managing Barrett esophagus. No randomized controlled trials have confirmed that screening patients with Barrett esophagus reduces mortality from esophageal adenocarcinoma; screening, endoscopic surveillance, and endoscopic eradication therapy have been shown to reduce the incidence of esophageal adenocarcinoma and improve early detection.&#x000a0;The&#x000a0;ACG now recommends screening for Barrett esophagus in&#x000a0;people with chronic symptoms of GERD who also have at least 3 additional risk factors, including male genotype, age&#x000a0;older than 50,&#x000a0;White race,&#x000a0;past&#x000a0;or present tobacco smoking, central obesity, or a history of Barrett esophagus or esophageal adenocarcinoma in a first-degree relative.<xref ref-type="bibr" rid="article-18143.r3">[3]</xref><xref ref-type="bibr" rid="article-18143.r14">[14]</xref><xref ref-type="bibr" rid="article-18143.r15">[15]</xref><xref ref-type="bibr" rid="article-18143.r16">[16]</xref>&#x000a0;</p>
        <p>Esophagogastroduodenoscopy with forceps biopsies is the gold-standard diagnostic test.&#x000a0;Wide-area transepithelial sampling with brushing of the entire surface of the Barrett epithelium may add to the yield of standard endoscopy with forceps biopsies; this technique has not yet been incorporated into the ACG guideline. High-definition white light and chromoendoscopy, using topical acetic acid or electronic chromoendoscopy, increase sensitivity and specificity for identifying dysplasia and adenocarcinoma.<xref ref-type="bibr" rid="article-18143.r17">[17]</xref>&#x000a0;Artificial intelligence is being evaluated in the United States and the Netherlands to develop a system that will identify neoplasia and the most abnormal areas as the optimal sites for biopsy.<xref ref-type="bibr" rid="article-18143.r18">[18]</xref>&#x000a0;However, the cost of&#x000a0;sedated endoscopy&#x000a0;and the small risk of complications have raised interest in developing alternative diagnostic testing. Such alternatives include unsedated transnasal endoscopy that non-clinicians can perform and the use of&#x000a0;one of several commercially available&#x000a0;swallowable capsule sponges combined with a biomarker such as a methylated deoxynucleic acid marker or trefoil factor 3.</p>
        <p>In cases of Barrett esophagus, the pathologist must determine whether dysplasia or carcinoma is present. Study results suggest that the extent of dysplasia also correlates with the risk of cancer, so it may be valuable for pathologists to comment not only on the presence of but also on the extent of dysplasia (such as focal or diffuse). Sometimes, there may be a specific concern for dysplasia if an area of nodularity or ulceration is noted during endoscopy.</p>
        <p>Barrett esophagus-related dysplasia is often flat and not apparent on endoscopy. The major histologic pattern of dysplasia is intestinal, therefore resembling an adenoma of the colon. Non-intestinal dysplasia also exists, including foveolar and serrated patterns; validated criteria for classification as either low- or high-grade dysplasia only exist for intestinal-type dysplasia. The distinction between high-grade dysplasia and intramucosal carcinoma suffers from a high degree of interobserver variability.<xref ref-type="bibr" rid="article-18143.r11">[11]</xref><xref ref-type="bibr" rid="article-18143.r12">[12]</xref></p>
        <p>The diagnosis of Barrett esophagus requires&#x000a0;the endoscopic&#x000a0;appearance of at least a 1-cm length of "salmon-pink" columnar metaplasia proximal to the esophagogastric junction, defined as the top of the gastric folds, with&#x000a0;confirmation of intestinal metaplasia with goblet cells on biopsy evaluation. The British Society of Gastroenterology and the GERD Society Study Committee in Japan do not require the presence of&#x000a0;goblet cells to diagnose Barrett esophagus, and they base the diagnosis solely on columnar metaplasia. Due to the controversy over the significance of goblet cells, another alternative classification has been proposed, which allows the pathologist to state that there is columnar metaplasia and then further specify whether goblet cells are present or absent.</p>
        <p>To maximize the possibility of finding Barrett esophagus, dysplasia, and adenocarcinoma, the ACG recommends a minimum of 8 biopsies,&#x000a0;2 from each quadrant, at 2 cm intervals for shorter segments of Barrett mucosa.<xref ref-type="bibr" rid="article-18143.r19">[19]</xref><xref ref-type="bibr" rid="article-18143.r20">[20]</xref>&#x000a0;The&#x000a0;Seattle protocol&#x000a0;calls&#x000a0;for segments greater than 4 cm long. The Seattle protocol involves taking biopsies of visible lesions, followed by 4-quadrant biopsies every 1 to 2 cm. Mixed results are seen when comparing the Seattle protocol to narrow-band imaging (NBI). Although NBI demonstrated endoscopically visible lesions and dysplasia better than simply utilizing the Seattle protocol,&#x000a0;NBI has not yet been incorporated into current guidelines.<xref ref-type="bibr" rid="article-18143.r21">[21]</xref></p>
        <p>The extent of Barrett esophagus is graded by the Prague criteria, specifying the circumferential length of Barrett epithelium at and above the top of the gastric folds (C) and the&#x000a0;maximum extent (M) of Barrett mucosa. The M criterion includes finger-like projections of Barrett epithelium proximal to the circumferentially involved segment. Islands of intestinal metaplasia are not considered in the Prague criteria, even if they are proximal to what would otherwise be considered the full length of Barrett mucosa. If the circumferential length is 6 cm and the maximal length is&#x000a0;8 cm, then the Prague classification would describe this lesion as C6M8.<xref ref-type="bibr" rid="article-18143.r22">[22]</xref><xref ref-type="bibr" rid="article-18143.r23">[23]</xref></p>
      </sec>
      <sec id="article-18143.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Multiple study results have initially suggested that endoscopic surveillance of patients with Barrett esophagus is associated with decreased esophageal adenocarcinoma-related deaths; this was not confirmed when adjustments were made for lead and length time biases. Based on&#x000a0;a systematic review of the literature and evaluation of the level of evidence, the ACG made several changes to the recommended management in its newest guidelines. High-definition white-light endoscopy is a novel endoscopic technology recommended for routine surveillance beyond electronic chromoendoscopy. When Barrett esophagus is found, the patient should be placed on&#x000a0;long-term proton pump inhibitor therapy, regardless of the presence of reflux symptoms, due to evidence of a chemopreventive effect of proton pump inhibitors, where the risk of progression to neoplastic&#x000a0;disease is reduced compared to no acid suppression or H2 blocker&#x000a0;treatment.</p>
        <p>Due to the significant impact on management, if Barrett esophagus is associated with dysplasia, the ACG emphasizes the importance of confirming any dysplasia diagnosis with a second expert pathologist with extensive experience in Barrett esophagus-related neoplasia. Surveillance protocols differ for the level of dysplasia seen as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>No dysplasia: An endoscopy is recommended every&#x000a0;3 years if the Barrett segment is &#x0003c;3 cm long or every&#x000a0;5 years if&#x000a0;the segment is at least 3 cm in length.</p>
          </list-item>
          <list-item>
            <p>Indefinite dysplasia: Guidelines recommend that endoscopy should be repeated&#x000a0;in 6 months on&#x000a0;twice-daily proton pump inhibitor therapy, with doses taken 30 to 45 minutes before a meal.<xref ref-type="bibr" rid="article-18143.r24">[24]</xref>&#x000a0;If the repeat endoscopy is unchanged, then the endoscopy should be repeated annually. If there is progression to low-grade dysplasia (LGD), then the LGD&#x000a0;management guideline should be followed.<xref ref-type="bibr" rid="article-18143.r2">[2]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>LGD: If endoscopic eradication therapy (EET) is declined or cannot be performed for any reason,&#x000a0;endoscopy should be repeated in 6 months, then again&#x000a0;6 months later, and then annually if the assessment of dysplasia does not change. EET for LGD is the same as for high-grade dysplasia (HGD), as described below.</p>
          </list-item>
          <list-item>
            <p>HGD: If there is flat mucosa with HGD (no mucosal abnormality is visible), EET is done to eliminate the entire area of metaplasia and dysplasia. Esophagectomy&#x000a0;is no&#x000a0;longer the preferred initial approach to managing HGD or intramucosal cancer, as the procedure has a high risk of morbidity. However, it should be considered if intramucosal cancer has poor prognostic factors, such as lymphovascular invasion or poor differentiation, or if cancer involves the submucosa. Patients with significant comorbidities that limit their likely survival may not benefit from endoscopic therapies, with risks of the procedures being greater than potential gains.<xref ref-type="bibr" rid="article-18143.r2">[2]</xref><xref ref-type="bibr" rid="article-18143.r25">[25]</xref><xref ref-type="bibr" rid="article-18143.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>Endoscopic eradication therapy is used to treat LGD, HGD, and early-stage esophageal adenocarcinoma and is preferable to endoscopic surveillance and acid-suppressive medication alone.<xref ref-type="bibr" rid="article-18143.r27">[27]</xref> These therapeutic techniques include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Radiofrequency ablation: Several (usually 3-4) applications of&#x000a0;radiofrequency ablation are applied to the Barrett mucosa using devices that ablate 90&#x000b0;, 180&#x000b0;, or 360&#x000b0; of the affected area at a time.&#x000a0;Complications of radiofrequency ablation include chest pain for up to 14 days, and less common but more serious complications include aspiration, bleeding, surface lacerations or deeper perforation, and strictures. This technique has effectively eradicated Barrett mucosa and dysplasia and is the preferred ablative modality for EET of flat dysplasia.<xref ref-type="bibr" rid="article-18143.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Cryotherapy: This can be performed using either liquid nitrogen cryospray or cryotherapy applied through an inflated balloon that compresses the Barrett segment.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hybrid argon plasma coagulation: This technique can be used for small islands of intestinal metaplasia. However, if used circumferentially, it has a relatively high rate of strictures.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) is used to resect nodules or masses,&#x000a0;followed by ablation of the remaining Barrett esophagus mucosa. EMR is preferred for smaller and more superficial neoplasia. At the same time, ESD is needed for more extensive lesions, if at least T1b&#x000a0;a&#x000a0;carcinoma invasion is highly suspected, or if EMR has failed to resect the lesion and all neoplastic tissue completely. If there is only a small Barrett esophagus&#x000a0;patch around the visible lesion, complete resection using EMR or ESD is preferable to later radiofrequency ablation, which requires multiple endoscopic sessions.</p>
          </list-item>
        </list>
        <p>Endoscopic surveillance must be continued after complete eradication of intestinal metaplasia (CEIM) and complete eradication of neoplasia. Biopsies should be taken of any visible lesions randomly from the cardia and the distal 2 cm of the esophagus, where recurrences are most likely to occur.<xref ref-type="bibr" rid="article-18143.r29">[29]</xref>&#x000a0;Based on the most advanced histology found before EET, the recommended intervals are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>LGD: Repeat endoscopy&#x000a0;1 year after CEIM, then&#x000a0;2 years later, then at nondysplastic Barrett esophagus intervals (every 3 to 5 years)&#x000a0;if there has been&#x000a0;no recurrence of metaplasia or dysplasia.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>HGD: Repeat endoscopy at 3, 6,&#x000a0;and 12 months following&#x000a0;CEIM. If there has been no recurrence at that point, the endoscopy should be repeated annually.</p>
          </list-item>
          <list-item>
            <p>Intramucosal esophageal adenocarcinoma:&#x000a0;Repeat endoscopy at 3, 6,&#x000a0;and 12 months following&#x000a0;CEIM. If there has been no recurrence of dysplasia or malignancy at that point, endoscopy should be repeated annually.</p>
          </list-item>
        </list>
        <p>EET is more cost-effective than endoscopic surveillance.<xref ref-type="bibr" rid="article-18143.r30">[30]</xref> When well-experienced endoscopists perform EET, intestinal metaplasia and neoplasia recurrence rates are lower.<xref ref-type="bibr" rid="article-18143.r31">[31]</xref>&#x000a0;If EET fails to achieve CEIM, management options include improving reflux control with a higher proton pump inhibitor dose, changing to a potassium-competitive acid blocker (P-CAB), fundoplication surgery, or repeating EET. However, P-CAB medications have yet to be tested for this indication.<xref ref-type="bibr" rid="article-18143.r32">[32]</xref></p>
        <p>Many case series report short-term Barrett outcomes; there are very&#x000a0;few studies on long-term outcomes. Even though there are several types of treatments for Barrett and GERD, there is no solid evidence to indicate which one is the best or most effective. With the availability&#x000a0;of EET, more long-term studies are needed to determine the safety of these procedures and their effectiveness in preventing the progression of Barrett esophagus to a malignancy.<xref ref-type="bibr" rid="article-18143.r33">[33]</xref></p>
      </sec>
      <sec id="article-18143.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When symptoms are present (eg, GERD) the differential diagnosis of Barrett esophagus is based on endoscopic findings and includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Esophageal mucosa with gastric metaplasia: This is identical in endoscopic appearance to Barrett esophagus (intestinal metaplasia), but biopsies show gastric fundic- or junctional-type epithelium instead. These types of gastric metaplasia are not risk factors for esophageal cancer.</p>
          </list-item>
          <list-item>
            <p>Acute gastritis</p>
          </list-item>
          <list-item>
            <p>Chronic gastritis with or without <italic toggle="yes">Helicobacter pylori</italic> infection</p>
          </list-item>
          <list-item>
            <p>Coronary artery atherosclerosis</p>
          </list-item>
          <list-item>
            <p>Reflux esophagitis</p>
          </list-item>
          <list-item>
            <p>Esophageal cancer</p>
          </list-item>
          <list-item>
            <p>Esophageal motility disorders</p>
          </list-item>
          <list-item>
            <p>Gallstones</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18143.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of Barrett esophagus largely depends on the degree of dysplasia present at the time of diagnosis and the effectiveness of surveillance and treatment strategies. While Barrett esophagus itself is a premalignant condition, the risk of progression to esophageal adenocarcinoma increases with the severity of dysplasia. Patients with nondysplastic Barrett esophagus have a relatively low risk of cancer progression, estimated at less than 0.5% per year. However, the presence of low- or high-grade dysplasia significantly raises this risk, with high-grade dysplasia carrying the highest potential for malignancy.</p>
        <p>Early detection and regular surveillance, along with timely endoscopic or surgical intervention, can improve the prognosis by preventing the progression to esophageal adenocarcinoma, a cancer associated with high morbidity and mortality. Advances in endoscopic eradication techniques have further enhanced outcomes, offering less invasive options with curative potential for patients with dysplastic Barrett esophagus. Therefore, the overall prognosis is favorable when Barrett esophagus is closely monitored and managed according to current guidelines. Average life expectancy with Barrett esophagus should be anticipated in the absence of&#x000a0;malignancy or other life-threatening conditions.&#x000a0;</p>
      </sec>
      <sec id="article-18143.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Untreated Barrett esophagus may progress into adenocarcinoma. However, the rate of progression is prolonged, and more than 95% of patients with Barrett esophagus will never develop malignancy. The number of adenocarcinoma cases has steadily increased over the past several decades.<xref ref-type="bibr" rid="article-18143.r34">[34]</xref>&#x000a0;There is an increasing risk of malignancy if Barrett mucosa is associated with greater degrees of dysplasia and with longer lengths of the Barrett segment. Complications of reflux esophagitis, such as bleeding&#x000a0;or ulceration, may be somewhat more likely with Barrett esophagus than without it. Still, strictures&#x000a0;and aspiration are no more&#x000a0;frequent with Barrett esophagus than without it.</p>
      </sec>
      <sec id="article-18143.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Smoking and obesity are risk factors for esophageal adenocarcinoma, so smoking cessation and weight loss, if necessary, should be advised. The role of diet in the etiology of Barrett esophagus remains inconclusive, but it should be no different from dietary recommendations for patients with GERD. Following a low-fat and high-fiber diet is best.</p>
        <p>Further recommendations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Avoid fried&#x000a0;or fatty foods, spicy foods, alcohol, caffeinated and carbonated beverages, chocolate, acidic juices, and tomato sauce.</p>
          </list-item>
          <list-item>
            <p>Have multiple small meals throughout the day rather than&#x000a0;2 or&#x000a0;3 large meals.</p>
          </list-item>
          <list-item>
            <p>Avoid eating or drinking for 4 hours before bedtime.</p>
          </list-item>
          <list-item>
            <p>Weight loss is beneficial in patients who are overweight.<xref ref-type="bibr" rid="article-18143.r35">[35]</xref><xref ref-type="bibr" rid="article-18143.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18143.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Because not all patients will progress from Barrett esophagus to cancer, an essential area of research is the development of reliable risk-profiling methods to identify patients at higher risk and those who will benefit more from therapies. The use of biomarkers to risk-stratify patients is currently&#x000a0;undergoing extensive research, with deoxyribonucleic acid content abnormalities and <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic>&#x000a0;alterations showing the most promise to date. Newer alternatives to endoscopy&#x000a0;for screening are being assessed to reduce cost and risk, including transnasal endoscopy and capsule sponges.&#x000a0;Other ongoing and future studies should add to our current knowledge base regarding Barrett esophagus and its best evaluation and management.</p>
      </sec>
      <sec id="article-18143.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The incidence of adenocarcinoma of the esophagus is increasing in most Western nations, and this change is undoubtedly due to Barrett esophagus. The progression of&#x000a0;Barrett esophagus to cancer is slow, but once cancer occurs, the prognosis is very poor. Over the years, multiple societies have developed guidelines for screening, surveillance, and managing Barrett esophagus.<xref ref-type="bibr" rid="article-18143.r15">[15]</xref><xref ref-type="bibr" rid="article-18143.r37">[37]</xref> Since most patients may have no symptoms or symptoms of reflux, suspicion of Barrett esophagus must always be increased, especially in high-risk populations. Unfortunately, many gastroenterologists and surgeons have been performing upper endoscopies&#x000a0;without clear-cut evidence that this procedure can detect esophageal cancer early or prevent cancer. Unnecessary endoscopies also lead to high healthcare costs.</p>
        <p>Thus, the recommendations are that one follow strict guidelines for surveillance based on patient risk factors rather than empirically performing endoscopy in all patients with chronic GERD. An interprofessional approach with a team of pathologists, thoracic surgeons, radiologists, gastroenterologists, and general surgeons will permit individualized care and the best results. The nurse's role is vital in educating the patient about reflux and ways to prevent it. The pharmacist should ensure that patients are adequately treated for reflux and have a referral to a gastroenterologist or primary care clinicians to manage therapy.<xref ref-type="bibr" rid="article-18143.r38">[38]</xref><xref ref-type="bibr" rid="article-18143.r39">[39]</xref>&#x000a0;Pharmacists will verify all acid-reducing medication strategies (eg, proton pump inhibitors or H2-receptor blockers), verify dosing and drug interactions, counsel patients on administration and adverse events, and report back to the prescriber with any concerns.</p>
        <p>A comprehensive care strategy for&#x000a0;patients with Barrett esophagus involves implementing evidence-based guidelines for screening, surveillance, and treatment. This strategy should include risk assessment protocols, personalized treatment plans, and the use of the latest EET techniques. Proactive management and regular surveillance are crucial to preventing the progression of Barrett esophagus to esophageal adenocarcinoma.</p>
        <p>By focusing on patient-centered care, health professionals can enhance patient outcomes and safety. This approach involves engaging patients in their care, respecting their preferences, and providing comprehensive education about their condition and treatment options. The multidisciplinary team works together to ensure that care is effective and aligned with the patient's goals and values, ultimately leading to better outcomes and a higher standard of patient safety.</p>
      </sec>
      <sec id="article-18143.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18143&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18143">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/barrett-esophagus-barrett-esophagus/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18143">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18143/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18143">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18143.s17">
        <fig id="article-18143.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Barrett Esophagus. Squamocolumnar junction with focal goblet cells. San Antonio Military Medical Center Case Files</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BE__statpearls" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18143.s18">
        <title>References</title>
        <ref id="article-18143.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaheen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Gerson</surname>
                <given-names>LB</given-names>
              </name>
              <collab>American College of Gastroenterology</collab>
            </person-group>
            <article-title>ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-50; quiz 51</page-range>
            <pub-id pub-id-type="pmid">26526079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaheen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Yadlapati</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>117</volume>
            <issue>4</issue>
            <fpage>559</fpage>
            <page-range>559-587</page-range>
            <pub-id pub-id-type="pmid">35354777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michopoulos</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus.</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>6</volume>
            <issue>13</issue>
            <fpage>259</fpage>
            <pub-id pub-id-type="pmid">30094245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nowicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kula</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>&#x0015a;wierszczy&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Barrett&#x00026;apos;s esophagus and gland cancer - the experience of one center.</article-title>
            <source>Pol Przegl Chir</source>
            <year>2018</year>
            <month>May</month>
            <day>16</day>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>19</fpage>
            <page-range>19-24</page-range>
            <pub-id pub-id-type="pmid">30015321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Patowary</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bhattarai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Barrett's Esophagus in Patients with Gastroesophageal Reflux Disease.</article-title>
            <source>J Nepal Health Res Counc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>03</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-148</page-range>
            <pub-id pub-id-type="pmid">29983427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inadomi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alastal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bonavina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Mashimo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>di Pietro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tolone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in Barrett's esophagus.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>1434</volume>
            <issue>1</issue>
            <fpage>227</fpage>
            <page-range>227-238</page-range>
            <pub-id pub-id-type="pmid">29974975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qumseya</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bukannan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gendy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahemd</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>707</fpage>
            <page-range>707-717.e1</page-range>
            <pub-id pub-id-type="pmid">31152737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Er&#x00151;ss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vincze</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Tinusz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Szap&#x000e1;ry</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balask&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarl&#x000f3;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Czopf</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alizadeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rakonczay</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Habon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hegyi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Helicobacter pylori infection reduces the risk of Barrett's esophagus: A meta-analysis and systematic review.</article-title>
            <source>Helicobacter</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>e12504</fpage>
            <pub-id pub-id-type="pmid">29938864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thrift</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?</article-title>
            <source>Dig Dis Sci</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>1988</fpage>
            <page-range>1988-1996</page-range>
            <pub-id pub-id-type="pmid">29671158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naini</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Odze</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2016</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>e45</fpage>
            <page-range>e45-66</page-range>
            <pub-id pub-id-type="pmid">26813745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunbar</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk.</article-title>
            <source>Gastrointest Endosc Clin N Am</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-459</page-range>
            <pub-id pub-id-type="pmid">28577766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ooi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blaker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DeMartino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Donohue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reffitt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lanaspre</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meenan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Dedicated Barrett's surveillance sessions managed by trained endoscopists improve dysplasia detection rate.</article-title>
            <source>Endoscopy</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>524</fpage>
            <page-range>524-528</page-range>
            <pub-id pub-id-type="pmid">28399610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Ococks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devonshire</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AWT</given-names>
              </name>
              <name>
                <surname>O'Donovan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miremadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>H</given-names>
              </name>
              <collab>Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium</collab>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Understanding the malignant potential of gastric metaplasia of the oesophagus and its relevance to Barrett's oesophagus surveillance: individual-level data analysis.</article-title>
            <source>Gut</source>
            <year>2024</year>
            <month>Apr</month>
            <day>05</day>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>729</fpage>
            <page-range>729-740</page-range>
            <pub-id pub-id-type="pmid">37989565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellizzi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hafezi-Bakhtiari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Westerhoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marginean</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Riddell</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal pathologists' perspective on managing risk in the distal esophagus: convergence on a pragmatic approach.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>1434</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-45</page-range>
            <pub-id pub-id-type="pmid">29749623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clermont</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Clinical Guidelines Update on the Diagnosis and Management of Barrett's Esophagus.</article-title>
            <source>Dig Dis Sci</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>2122</fpage>
            <page-range>2122-2128</page-range>
            <pub-id pub-id-type="pmid">29671159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muthusamy</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gyawali</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Komanduri</surname>
                <given-names>S</given-names>
              </name>
              <collab>CGIT Barrett&#x02019;s Esophagus Consensus Conference Participants</collab>
            </person-group>
            <article-title>AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>2696</fpage>
            <page-range>2696-2706.e1</page-range>
            <pub-id pub-id-type="pmid">35788412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coletta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Nachiappan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fraquelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casazza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ragunath</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Acetic acid chromoendoscopy for the diagnosis of early neoplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-67.e1</page-range>
            <pub-id pub-id-type="pmid">26371851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Groof</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Struyvenberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>van der Putten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van der Sommen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fockens</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Curvers</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Zinger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pouw</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Coron</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baldaque-Silva</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pech</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weusten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meining</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bisschops</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schoon</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>de With</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Deep-Learning System Detects Neoplasia in Patients With Barrett's Esophagus With Higher Accuracy Than Endoscopists in a Multistep Training and Validation Study With Benchmarking.</article-title>
            <source>Gastroenterology</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>158</volume>
            <issue>4</issue>
            <fpage>915</fpage>
            <page-range>915-929.e4</page-range>
            <pub-id pub-id-type="pmid">31759929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ak&#x00131;n</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ayd&#x00131;n</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>How should we describe, diagnose and observe the Barrett's esophagus?</article-title>
            <source>Turk J Gastroenterol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>Suppl 1</issue>
            <fpage>S26</fpage>
            <page-range>S26-S30</page-range>
            <pub-id pub-id-type="pmid">29199163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ragunath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wyman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trudgill</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Veitch</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS).</article-title>
            <source>Gut</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>1886</fpage>
            <page-range>1886-1899</page-range>
            <pub-id pub-id-type="pmid">28821598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hawes</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Curvers</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gaddam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fockens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial.</article-title>
            <source>Gut</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">22315471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vahabzadeh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Seetharam</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Early</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Validation of the Prague C &#x00026; M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>236</fpage>
            <page-range>236-41</page-range>
            <pub-id pub-id-type="pmid">22248595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gossner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hoshihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Junghard</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lundell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tytgat</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Vieth</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C &#x00026; M criteria.</article-title>
            <source>Gastroenterology</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>1392</fpage>
            <page-range>1392-9</page-range>
            <pub-id pub-id-type="pmid">17101315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>di Pietro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ragunath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trudgill</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Donovan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bird-Lieberman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Attwood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Loft</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lagergren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lyratzopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Caestecker</surname>
                <given-names>J</given-names>
              </name>
              <collab>British Society of Gastroenterology</collab>
            </person-group>
            <article-title>British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.</article-title>
            <source>Gut</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-42</page-range>
            <pub-id pub-id-type="pmid">24165758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markar</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Arhi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leusink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vidal-Diez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karthikesalingam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Darzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lagergren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>The Influence of Antireflux Surgery on Esophageal Cancer Risk in England: National Population-based Cohort Study.</article-title>
            <source>Ann Surg</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>268</volume>
            <issue>5</issue>
            <fpage>861</fpage>
            <page-range>861-867</page-range>
            <pub-id pub-id-type="pmid">30048317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-175</page-range>
            <pub-id pub-id-type="pmid">29928161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubenstein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sawas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chandar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Perumpail</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Inadomi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thrift</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Piscoya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katzka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davitkov</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.</article-title>
            <source>Gastroenterology</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>166</volume>
            <issue>6</issue>
            <fpage>1020</fpage>
            <page-range>1020-1055</page-range>
            <pub-id pub-id-type="pmid">38763697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaheen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Overholt</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Wolfsen</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Sampliner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Galanko</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bronner</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Goldblum</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Jobe</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fennerty</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Hawes</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rothstein</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mashimo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Muthusamy</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Edmundowicz</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Spechler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Infantolino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Kimmey</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Madanick</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lightdale</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation in Barrett's esophagus with dysplasia.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>May</month>
            <day>28</day>
            <volume>360</volume>
            <issue>22</issue>
            <fpage>2277</fpage>
            <page-range>2277-88</page-range>
            <pub-id pub-id-type="pmid">19474425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ezekwe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boniface</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edmundowicz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obuch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cinnor</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brauer</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Early</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Mullady</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kushnir</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Komanduri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muthusamy</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Anatomic location of Barrett's esophagus recurrence after endoscopic eradication therapy: development of a simplified surveillance biopsy strategy.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-403</page-range>
            <pub-id pub-id-type="pmid">31004598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubenstein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Inadomi</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma.</article-title>
            <source>Gastrointest Endosc Clin N Am</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-90</page-range>
            <pub-id pub-id-type="pmid">33213801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kanthasamy</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pompeii</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>El-Serag</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Thrift</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72.e5</page-range>
            <pub-id pub-id-type="pmid">29902646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sunkara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ofosu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaduputi</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?</article-title>
            <source>World J Gastrointest Pharmacol Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <day>13</day>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>63</fpage>
            <page-range>63-68</page-range>
            <pub-id pub-id-type="pmid">30595950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Codipilly</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Chandar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaheen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Inadomi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.</article-title>
            <source>Gastroenterology</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>154</volume>
            <issue>8</issue>
            <fpage>2068</fpage>
            <page-range>2068-2086.e5</page-range>
            <pub-id pub-id-type="pmid">29458154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bresalier</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.</article-title>
            <source>Dig Dis Sci</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>2155</fpage>
            <page-range>2155-2162</page-range>
            <pub-id pub-id-type="pmid">29948566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meining</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Classen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>10</issue>
            <fpage>2692</fpage>
            <page-range>2692-7</page-range>
            <pub-id pub-id-type="pmid">11051337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Body-mass index and symptoms of gastroesophageal reflux in women.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Jun</month>
            <day>01</day>
            <volume>354</volume>
            <issue>22</issue>
            <fpage>2340</fpage>
            <page-range>2340-8</page-range>
            <pub-id pub-id-type="pmid">16738270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedberg</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YX</given-names>
              </name>
            </person-group>
            <article-title>The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.</article-title>
            <source>Gastroenterology</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>706</fpage>
            <page-range>706-715</page-range>
            <pub-id pub-id-type="pmid">28257716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Mohiuddin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bodnar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>El Lakis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary treatment of T1a adenocarcinoma in Barrett's esophagus: contemporary comparison of endoscopic and surgical treatment in physiologically fit patients.</article-title>
            <source>Surg Endosc</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>8</issue>
            <fpage>3391</fpage>
            <page-range>3391-401</page-range>
            <pub-id pub-id-type="pmid">26541725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18143.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garside</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Somerville</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.</article-title>
            <source>Health Technol Assess</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>1</fpage>
            <page-range>1-142, iii-iv</page-range>
            <pub-id pub-id-type="pmid">16545207</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
